The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis is an international leader in moving laboratory and preclinical research into clinical practice. More than 350 Washington University physicians and scientists treat more than 8600 patients with newly diagnosed cancer each year, making Siteman one of the largest cancer centers in the United States. These faculty members receive nearly $140 million annually for basic and clinical oncology research grants. Siteman offers patients a diverse spectrum of 340 therapeutic clinical trials, and more than one-third of newly diagnosed patients are enrolled in therapeutic trials. Siteman also is the premier center for innovative leukemia research, and the National Cancer Institute has awarded Siteman leukemia researchers their third Program Project Grant and an $11.3 million SPORE grant. The purpose of this prospective cohort study was to assess the feasibility of outpatient treatment in patients with cancer and objectively confirmed pulmonary embolism, and to compare the performance of the different prognostic scales available in this setting. 
Screening Process Failures for Hepatocellular Carcinoma

Chemotherapy Hypersensitivity Reactions in Ovarian Cancer
Matthieu Picard, MD; Ursula A. Matulonis, MD; and Mariana Castells, MD, PhD
Chemotherapy using a taxane and platinum combination is key in improving survival in patients with ovarian cancer. However, hypersensitivity reactions to chemotherapeutic agents are increasingly common and can greatly limit their use. Efforts are needed to increase awareness about desensitization procedures so that more patients may benefit.
FOCUSED REVIEWS
Developing Guidelines for Cervical Cancer Prevention in the
Face of Diagnostic Complexity
L. Stewart Massad, MD
Adoption of new cervical cancer screening guidelines by the American Cancer Society and others in 2012 required new guidelines for the management of abnormal screening and followup tests. Because of the increasing number of available tests and the increasingly nuanced understanding of risk mean, clinicians will need to offset the complexity of diagnostic and treatment algorithms with technology and specialization.
Unanswered Questions in the Management of Stage I-III
Merkel Cell Carcinoma
Jonathan S. Zager, MD; Jane L. Messina, MD; L. Frank Glass, MD; and Vernon K. Sondak, MD
Many unanswered questions remain about what constitutes appropriate guidelines for the treatment of Merkel cell carcinoma. This review addresses current uncertainty surrounding optimal management, including early recognition features, clinical and histopathologic prognostic factors, optimum margins of excision of the primary tumor, indications for and value of surgical staging of the clinically negative regional nodes, optimum management of the patient with pathologically positive regional nodes, and indications for and value of radiation to the primary and regional nodes. 
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Supplements Available Online at JNCCN.org Metastatic Colorectal Cancer
Vol 11; Suppl 4, 2013 www.jnccn.org/content/11/suppl_4
The past decade has enriched our understanding of colorectal cancer biology and added complexity to the therapeutic armamentarium for patient with advanced disease. In this special supplement to JNCCN, multiple articles integrate a spectrum of treatment approaches, strategies, and challenges, reflecting comprehensive care for patients with metastatic colorectal cancer. Articles include a case report on management of the patient with synchronous metastatic rectal cancer; a discussion of KRAS and multigene assays, including their current and potential uses in colorectal cancer; a summary of the array of treatment opportunities for metastatic colorectal cancer patients, and a discussion of treatment sequencing in advanced unresectable disease. Finally, the early introduction of palliative care for patients with advanced disease is discussed. Most of the articles offer individual CE.
NCCN Task Force Report: Bone Health in Cancer Care
Vol 11; Suppl 3, 2013 www.jnccn.org/content/11/suppl_3
This report is the result of a multidisciplinary task force on bone health in cancer care convened by NCCN to discuss the progress made in assessing bone health; cancer therapy and bone loss; therapeutic strategies for maintaining bone health in patients with cancer; role of antiresorptive agents in preventing recurrences; pathophysiology of bone metastases and its complications; imaging and treatment of bone metastases; and safety and toxicity considerations while using antiresorptive agents. This NCCN Task Rorce report focuses on bone health and bone metastases in patients with breast and prostate cancer. Rising health care costs and continued concerns about safety, efficacy, and quality have resulted in the demand for more data and evidence by payors, regulators, providers, and patients alike. In June 2012, NCCN assembled a work group composed of thought leaders from NCCN Member Institutions and other organizations to identify and examine the challenges of data generation, collection, and application for clinical, regulatory, and coverage decisionmaking. The NCCN Data Needs Work Group identified 4 main areas for consideration: data sources, patient-derived data, payor-collected data, and regulatory policy toward data generation and use.
Data Needs in
Early Initiation of Palliative Care Interventions in Patients With Cancer, With an Emphasis on Management of Breakthrough Pain
Vol 11; Suppl 1, 2013 www.jnccn.org/content/11/suppl_1
Optimal cancer care requires the integration of palliative care into practice. A group of international experts met to review the current status of concurrent palliative and oncology care in different countries and to address questions related to why this integration does not occur on a more regular and effective basis. This supplement is a product of these discussions, which focused on key issues: development of a standard definition of palliative care and its component parts; models for care delivery; standardization of tools for patient assessment; educational programs designed to meet the needs of health care professionals; and the importance of developing best practices in symptom management using breakthrough pain management as an example.
White Paper: Equity in Cancer Care: Pathways, Protocols, and Guidelines Vol 10; Suppl 1, 2012 www.jnccn.org/content/10/suppl_1
To meet a current need to discuss the use of clinical pathways and clinical treatment guidelines in oncology and address how patient care is impacted by their use, NCCN convened the NCCN Oncology Policy Summit: Equity in Cancer Care: Pathways, Protocols, and Guidelines. The summit featured discussions and presentations among diverse stakeholders, such as patient advocacy groups, policy-makers, payers, and pathway company representatives. This White Paper explores the use of guidelines and pathways in oncology and incorporates the discussions and ideas raised at the summit.
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